CDSCO approves Servier India's Vorasidenib for IDH-mutant glioma

• Servier India received CDSCO marketing approval for its brain cancer drug.
• The approved drug, Vorasidenib (Voranigo), targets Grade 2 IDH-mutant glioma.
• This approval addresses an unmet medical need for approximately 4,500 Indian patients annually, mostly young adults.

Why It Matters: New drug offers hope for young adults with a specific brain cancer.